glp 1 and gut microbiome Divergent roles for the intraepithelial lymphocyte GLP-1R in control of metabolism, microbiota, T cell-induced inflammation GLP-1 Therapy and the Gut

7f) without altering weights of several peripheral organs (Supplementary Fig

Very convincing data that combined therapy with SGLT-2i and GLP-1 RA is much more efficacious in decreasing CV, renal and HF outcomes than monotherapies This is somehing that all of us expects but we have no strong prospective randomized data Also, the safety of combination appears to be fine Nice paper on a very important topic

Previous independent reporting examining ColonBroom GLP-1 Booster explored the product's market entry, initial consumer reception, and formula positioning within the non-prescription metabolic support category

MST L-Carnitine CLA , ,

The SURMOUNT-4 trial presents another opportunity for tirzepatide to differentiate from Novos semaglutide